Research Article
Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia
Table 1
Clinical characteristics of de novo non-M3 AML patients according to the CD56 expression.
| | Variables | All patients, (%) | CD56-low, (%) | CD56-high, (%) | value |
| | No. of patients | 89 (100) | 63 (70.79) | 26 (29.21) | | | Sex | | | | | | Male | 42 (47.19) | 24 (38.10) | 18 (69.23) | 0.343 | | Female | 47 (52.81) | 39 (61.90) | 8 (30.77) | | | Age, years | | | | 0.143 | | Mean (min-max) | 39 (12~64) | 41 (13~64) | 36 (12~61) | | | BM blasts (%) | | | | 0.244 | | Median | 67.70 | 63.39 | 73.20 | | | Range | 15.57~97.25 | 15.57~97.25 | 33.50~95.00 | | | WBC (×109/L) | | | | 0.632 | | Mean (min-max) | 39.76 (0.59~365.67) | 41.55 (0.95~365.67) | 35.19 (1.28~148.90) | | | HB (g/dL) | | | | 0.336 | | Mean (min-max) | 76.03 (1.78~149.00) | 77.71 (1.78~149.00) | 71.65 (37~107) | | | PLT (×109/L) | | | | 0.010 | | Median | 27.00 | 32.5 | 21.5 | | | Range | 3~301 | 3~301 | 5~83 | | | FAB classification | | | | 0.471 | | M1 | 9 (10.11) | 5 (7.94) | 4 (15.38) | | | M2 | 27 (30.34) | 20 (31.75) | 7 (26.92) | | | M4 | 28 (31.46) | 24 (38.10) | 4 (15.38) | | | M5 | 15 (16.85) | 11 (17.46) | 4 (15.38) | | | Unclassified | 5 (5.62) | 3 (4.76) | 2 (7.69) | | | Cytogenetic risk | | | | 0.274 | | Favorable | 9 (10.11) | 5 (7.94) | 4 (15.38) | | | Intermediate | 61 (68.54) | 43 (68.25) | 18 (69.23) | | | Adverse | 19 (21.35) | 15 (23.81) | 4 (15.38) | | | Received BMT | | | | 1.000 | | BMT | 15 (16.85) | 11 (17.46) | 4 (15.38) | | | Without BMT | 74 (83.15) | 52 (82.54) | 22 (84.62) | |
|
|
BM: bone marrow; WBC: white blood cell; Hb: hemoglobin; PLT: platelet; BMT: bone marrow transplantation.
|
